News: Featured cover paper
Addiction to Runx1 is partially attenuated by loss of p53 in the Eµ-Myc lymphoma model
Oncotarget is a multidisciplinary traditional journal with free-access. Oncotarget publishes papers online in weekly issues. Each issue or paper can be printed for special demand.
Starting August 2015, Oncotarget goes weekly
Our mission is to make scientific results rapidly and widely available. To maximize the impact of research via insightful review. To allow exceptional discoveries to be shared quickly. To eliminate the border between specialties. To link different fields of biomedical science. To foster applications of basic and clinical science to fight disease.
Under the leadership of the most prominent scientists, the journal helps all researchers contribute to the progress of science. Life without disease is our ultimate goal.
The success of Oncotarget has prompted us to launch sections beyond oncology.
The term "oncotarget" encompasses all molecules, pathways, and cellular functions common in cancer and aging, neurodegeneration and atherosclerosis, lymphocytes and neurons, cancer cells and microbes.
Oncotarget is launching sections on:
- Pathology beyond oncology
- Immunology and Microbiology
- Autophagy and Cell Death
- Precision Medicine
- Circadian Rhythm
Impact factor (IF)
ISI/Thomson Reuters JCR
- 2014: 6.359
- 2013: 6.627
- 2012: 6.636
- 2011: 4.784
5-Year Impact Factor:
- MEDLINE/PubMed and PMC
- Science Citation Index Expanded/
Web of Science
- Scopus: Ranks Q1
If your paper was mistakenly rejected by other leading journals, you may submit it to Oncotarget together with peer-reviews obtained from the other journal and rebuttal letter.
100 Plus Papers from the Editorial Board:
See full list
See Oncotarget in the global News
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
Copyright @ 2008-2016 Impact Journals, LLC. All rights reserved.
Impact Journals is a trademark of Impact Journals, LLC .